





## RESEARCH ARTICLE

# Atopic biomarker changes after exposure to *Porphyromonas gingivalis* lipopolysaccharide: a small experimental study in Wistar rats [version 1; peer review: awaiting peer review]

Sindy Cornelia Nelwan<sup>1</sup>, Ricardo Adrian Nugraha <sup>2</sup>, Anang Endaryanto<sup>3</sup>, Asti Meizarini<sup>4</sup>, Udijanto Tedjosongko<sup>1</sup>, Seno Pradopo<sup>1</sup>, Haryono Utomo<sup>5</sup>, Nunthawan Nowwarote <sup>6</sup>

<sup>1</sup>Department of Pediatric Dentistry, Universitas Airlangga, Surabaya, Jawa Timur, 60235, Indonesia

<sup>2</sup>Department of Cardiology and Vascular Medicine, Universitas Airlangga, Surabaya, Jawa Timur, 60235, Indonesia

<sup>3</sup>Division of Pediatric Allergy and Immunology, Department of Child Health, Universitas Airlangga, Surabaya, Jawa Timur, 60235, Indonesia

<sup>4</sup>Department of Dental Materials, Science and Technology, Universitas Airlangga, Surabaya, Jawa Timur, 60235, Indonesia

<sup>5</sup>Department of Forensic Odontology, Universitas Airlangga, Surabaya, Jawa Timur, 60235, Indonesia

<sup>6</sup>Centre de Recherche des Cordeliers, INSERM UMRS 1138, Molecular Oral Pathophysiology, Université de Paris, Sorbonne Université, Paris, 75006, France

**V1** First published: 11 May 2021, 10:371  
<https://doi.org/10.12688/f1000research.51959.1>

Latest published: 11 May 2021, 10:371  
<https://doi.org/10.12688/f1000research.51959.1>

## Abstract

**Background:** IgE and IgG<sub>4</sub> are implicated in atopic development and clinically utilized as major biomarkers. Atopic responses following certain pathogens, such as *Porphyromonas gingivalis* (Pg), are currently an area of interest for further research. The aim of this study is to measure the level of IgE, IgG<sub>4</sub>, and IgG<sub>4</sub>/IgE ratio periodically after exposure of periodontal pathogen Pg lipopolysaccharide (LPS).

**Methods:** We used 16 Wistar rats (*Rattus norvegicus*) randomly subdivided into four groups: Group 1, injected with placebo; Group 2, injected with LPS Pg 0.3 µg/mL; Group 3, injected with LPS Pg 1 µg/mL; and Group 4, injected with LPS Pg 3 µg/mL. Sera from all groups were taken from retro-orbital plexus before and after exposure.

**Results:** Levels of IgE and IgG<sub>4</sub> increased significantly following exposure of LPS Pg at day-4 and day-11. Greater increase of IgE rather than IgG<sub>4</sub> contributed to rapid decline of IgG<sub>4</sub>/IgE ratio, detected in the peripheral blood at day-4 and day-11.

**Conclusion:** Modulation of atopic responses following exposure to LPS Pg is reflected by a decrease in IgG<sub>4</sub>/IgE ratio that accompanies an increase of IgE. Therefore, Pg, a keystone pathogen during periodontal disease, may have a tendency to disrupt atopic biomarkers.

## Open Peer Review

**Reviewer Status** AWAITING PEER REVIEW

Any reports and responses or comments on the article can be found at the end of the article.

**Keywords**

allergic diseases, atopic inflammatory pathway, immunoglobulin, periodontal pathogen, Porphyromonas gingivalis LPS

**Corresponding author:** Sindy Cornelia Nelwan ([sindy-c-n@fkg.unair.ac.id](mailto:sindy-c-n@fkg.unair.ac.id))

**Author roles:** **Nelwan SC:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Project Administration; **Nugraha RA:** Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation; **Endaryanto A:** Resources, Software, Supervision, Validation, Writing – Review & Editing; **Meizarini A:** Resources, Software, Visualization; **Tedjosongko U:** Supervision, Writing – Review & Editing; **Pradopo S:** Supervision, Writing – Review & Editing; **Utomo H:** Funding Acquisition, Supervision, Visualization, Writing – Review & Editing; **Nowwarote N:** Supervision, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** The author(s) declared that no grants were involved in supporting this work.

**Copyright:** © 2021 Nelwan SC *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Nelwan SC, Nugraha RA, Endaryanto A *et al.* **Atopic biomarker changes after exposure to *Porphyromonas gingivalis* lipopolysaccharide: a small experimental study in Wistar rats [version 1; peer review: awaiting peer review]** F1000Research 2021, 10:371 <https://doi.org/10.12688/f1000research.51959.1>

**First published:** 11 May 2021, 10:371 <https://doi.org/10.12688/f1000research.51959.1>

## Introduction

The oral cavity is the habitat of numerous bacteria, including *Porphyromonas gingivalis* (Pg). Pg is a gram negative, facultative anaerobic pathogen, which is responsible in causing gingivitis or periodontitis.<sup>1</sup> In low-income countries, gingivitis and periodontitis can affect up to 90% of the adult population.<sup>2</sup> Rather than alveolar bone and ligament destruction, Pg is believed to be involved with the development of atopic responses in a susceptible host.<sup>3</sup> Following Pg infection, hosts' adaptive immune response (both cell-mediated and humoral-mediated) could induce a systemic inflammatory reaction, not only just local destruction of tooth-supporting tissues.<sup>4-5</sup> Although periodontal pathogens, such as Pg, play a major role in the initiation of local and systemic inflammatory reaction,<sup>6</sup> the host aberrant immune responses require further study. Since humoral immune responses are stimulated following Pg infection, there might be a link to the occurrence of atopy.

Despite long-standing research about hygiene hypothesis for several decades, there is an unequivocally accepted fact that the prevalence of atopy increases more among children who have periodontal pathogen colonization or infection.<sup>7</sup> While endorsing these hygiene hypothesis approaches, there is an alternative hypothesis in which exposure to some periodontal pathogens will exclusively trigger an "immunoglobulin-E skew" rather than reducing it.<sup>8</sup> Within the context of the hygiene hypothesis, the most essential microbial exposures needed to be studied is the biomolecular relationship between host antibody and regulatory T-cell with lipopolysaccharide (LPS), an endotoxin released by Pg to affect host immune reaction.

Hygiene hypothesis principles might not be able to answer all phenomenon of increasing incidence of atopy among children with poor oral hygiene.<sup>9</sup> Some studies report a positive association between the colonization/infection of Pg with the development of allergic diseases,<sup>10-15</sup> whereas some studies report no association.<sup>16-21</sup> Due to lack of conclusive evidence about the association between Pg and allergic diseases,<sup>22</sup> we try to measure the level of atopic biomarkers following Pg infection.

To the best of our knowledge, measuring IgG<sub>4</sub> and IgE antibody may have a closer association to atopic profiles, since IgG<sub>4</sub> and IgE are released after activation of mature B cells following the modulation of IL-4 and IL-5 released by Th-2 cells during type I hypersensitivity.<sup>23</sup> By looking at the alteration of IgG<sub>4</sub> and IgE antibodies level after exposure to these selected components of Pg in a rat model, we hope to understand more deeply the biological mechanism of B-cell production antibodies pattern and humoral immune responses before the clinical manifestation of atopy. We chose a rat model since they are inbred so they are almost identical genetically and their genetic, biological and behavior characteristics closely resemble those of humans.

## Methods

### Ethics approval

This article was reported in line with the ARRIVE guidelines. Animal experimental study was conducted under the approval of the Institutional Animal Research Ethics Committee of Universitas Airlangga (UNAIR), Surabaya, Indonesia (animal approval no:50/KKEPK.FKG/IV/2015) under the name of Sindy Cornelia Nelwan as the Principal Investigator. The study was carried out in strict accordance to internationally accepted standards of the Guide for the Care and Use of Laboratory Animals of the National Institute of Health. All efforts were made to ameliorate any suffering of animals through using anaesthetic to euthanize the rats at the end of the experimental procedure.

### Animals

#### Sample size

$N = (Z_{\alpha/2})^2 s^2/d^2$ , where  $s$  is the standard deviation obtained from previous study or pilot study, and  $d$  is the accuracy of estimate or how close to the true mean.  $Z_{\alpha/2}$  is normal deviate for two-tailed alternative hypothesis at a level of significance. Suppose sample size calculated by software is 3 animals per group and researcher is expecting 10% attrition then his final sample size will be 4 animals per group or 16 animals in total.

#### Rats

The present study used 16 male Wistar rats (*Rattus norvegicus*) between eight and ten weeks of age (average body weight 120-150 grams). The rats were housed in microisolator cages and maintained in a constant room temperature ranging from 22°C to 25°C, with a 12-h light/12-h dark cycle, under artificially controlled ventilation, with a relative humidity ranging from 50% to 60%. The rats were fed a standard balanced rodent diet (NUTRILAB CR-1®) and water were provided ad libitum.

Inclusion criteria was male Wistar rats, age 8-10 weeks, with body weight 120-150 grams. Female Wistar rats, diseased, sick, and lazy male Wistar rats were strictly excluded.

### Experimental design and groups

The present study design was a pre-test post-test-controlled unblinded group design using quantitative method. The 16 male Wistar rats were randomized using randomized block sampling and classified into four groups. Each group consisted of 4 matched Wistar rats (age, weight, IgE and IgG<sub>4</sub> baseline characteristic). Group 1 were given placebo (0.9% normal saline solution). Group 2 were given lipopolysaccharide (LPS) of *Porphyromonas gingivalis* (Pg) (American Type Culture Collection, Rockville, Md.) at dose 0.3 µg/mL. Group 3 were given LPS Pg at dose 1 µg/mL. Group 4 were given LPS Pg at dose 3 µg/mL.

The rats received LPS by an intra-sulcular injection. Intra-sulcular injection has an advantage due to its direct delivery of LPS to oral cavity in which the tip of needle is injected slowly at the crestal bone. Longitudinal quantitative measurement was performed; IgE level, IgG<sub>4</sub> level, and IgG<sub>4</sub>/IgE ratio in both groups on day-0 (before treatment), day-4, and day-11. An average of 0.2 ml peripheral blood sera was obtained by Pasteur pipette from retro-orbital plexus, using a lateral approach on each of these days from each rat. The potential expected adverse events were anaphylactic shock, allergic reaction, bleeding and infection. However, to the best of our knowledge, there were no expected nor unexpected adverse events in the experimental procedures. Following the end of the experiments, all efforts were made to ameliorate any suffering of animals through injection of sodium pentobarbital anesthetic to euthanize the rats at the end of the experimental procedure.

### Level of IgG<sub>4</sub> and IgE

Sample of the sera were collected and stored at -70°C (-94°F) at Institute of Tropical Diseases Universitas Airlangga (UNAIR). All sera were assessed by direct-sandwich enzyme-linked immunosorbent assay (ELISA) with mouse IgE antibody (MAB9935) and IgG<sub>4</sub> antibody (MAB9895) under the manufacturer's (R&D System Europe Ltd, Abingdon, UK) protocol. Briefly, the sera were examined using microtiter plates using 25 µl of 3,3',5,5'-tetramethylbenzidine to 1 ml of phosphate-citrate buffer plus perborate in a mildly acidic buffer (adjust pH 5.7). Levels of IgG<sub>4</sub> were detected using monoclonal antibody anti-IgG<sub>4</sub>, transferring it to microtiter plates, adding the supplied conjugate, adding blocking solution, diluting plasma sample (1:100,000), and washing between the steps. Level of IgE was detected using monoclonal antibody anti-IgE, following similar steps until diluting the plasma sample (1:200). A minimum value of 0.01 pg/mL for IgE and 0.01 ng/mL for IgG<sub>4</sub> were assigned for below the limit of detection. We used 3,3',5,5'-tetramethylbenzidine as chromogenic substrate, which allows direct visualization of signal development through spectrophotometer.

### Statistical analysis

All measurements were performed at least three times. Results were presented as means ± standard errors (SEM). The assumption of the normality for the complete data was assessed by Shapiro-Wilk test. Test of homogeneity of variances was assessed by Levene Statistics. Statistical significance was examined by one-way ANOVA and repeated measure ANOVA using SPSS version 17.0 for Microsoft (IBM corp, Chicago, USA).

## Results

### General characteristic investigations

**Table 1** show the baseline characteristics of the 16 Wistar rats (*Rattus norvegicus*). No significant differences were found for mean age ( $p = 0.774$ ), body weight ( $p = 0.700$ ), baseline IgE ( $p = 0.071$ ), baseline IgG<sub>4</sub> ( $p = 0.770$ ), and baseline IgG<sub>4</sub>/IgE ratio ( $p = 0.053$ ) among the four groups.

### Comparison of serum IgE level between the four groups

Prior to experiments (day-0), there was no difference of serum IgE level between the four groups ( $p > 0.05$ ). On day-4, there was a significance difference of serum IgE level between all groups ( $p = 0.006$ ). At day-4, the highest average IgE level could be found in Group 3 treated with LPS Pg 1 µg/ml ( $17.00 \pm 1.69$  pg/ml) and the lowest average IgE level could be found in Group 1 (control) ( $5.31 \pm 0.76$  pg/ml). On day-11, there was also a significance difference of serum IgE level between both groups ( $p = 0.047$ ). At day-11 the highest average IgE level could be found in Group 2 treated with LPS Pg 0.3 µg/ml ( $180.34 \pm 10.42$  pg/ml) and the lowest average IgE level could be found in Group 1 ( $5.06 \pm 1.86$  pg/ml) (**Table 2**).

### Comparison of serum IgG<sub>4</sub> level between the four groups

Prior to experiments (day-0), there was no difference of serum IgG<sub>4</sub> level between the four groups ( $p > 0.05$ ). On day-4, there was a significance difference of serum IgG<sub>4</sub> level between all groups ( $p = 0.008$ ). At day-4, the highest average IgG<sub>4</sub> level could be found in Group 4 (LPS Pg 3 µg/ml;  $23.86 \pm 1.59$  ng/ml) and the lowest average IgG<sub>4</sub> level could be found


**Table 1. General characteristics of study population (n = 16; 4/group).**

Variable	Group 1 (control)	Group 2 (LPS Pg 0.3 µg/ml)	Group 3 (LPS Pg 1 µg/ml)	Group 4 (LPS Pg 3 µg/ml)	p value
Age (weeks)	8.87 ± 0.86	9.37 ± 0.95	8.75 ± 0.96	9.12 ± 0.63	0.774
Weight (g)	135.25 ± 9.54	135.25 ± 9.55	137.25 ± 7.93	138.00 ± 10.98	0.700
Male (%)	100	100	100	100	-
IgE (pg/mL)	5.69 ± 0.28	5.36 ± 0.19	10.27 ± 0.70	6.69 ± 0.61	0.071
IgG <sub>4</sub> (ng/mL)	10.74 ± 1.41	11.76 ± 0.85	11.91 ± 1.66	10.14 ± 1.44	0.770
IgG <sub>4</sub> /IgE (x10 <sup>3</sup> )	1.87 ± 0.18	2.20 ± 0.13	1.19 ± 0.20	1.59 ± 0.34	0.053

\*Data are presented as mean ± standard error of the mean (SEM).

\*\*One-way ANOVA for categorical variables; significant at *p* < 0.05.

\*\*\*IgE, immune globulin E; IgG<sub>4</sub>, immune globulin G<sub>4</sub>; IgG<sub>4</sub>/IgE, ratio between average IgG<sub>4</sub> levels divided by average IgE levels.



**Figure 1. Longitudinal observation of serum IgE levels following exposure to LPS Pg.**

in Group 1 ( $8.34 \pm 0.58$  ng/ml). On day-11, there was a greater difference of serum IgG<sub>4</sub> level between all groups (*p* = 0.005). At day-10, the highest average IgG<sub>4</sub> level could be found in Group 4 (LPS Pg 3 µg/ml;  $63.74 \pm 4.74$  ng/ml) and the lowest average IgG<sub>4</sub> level could be found in Group 1 ( $13.91 \pm 0.99$  ng/ml) (Table 3).


**Ratio of IgG<sub>4</sub>/IgE antibodies between the four groups**

The average IgG<sub>4</sub>/IgE ratio for the control group at day-0, day-4, and day-11 was  $1.87 \times 10^3$ ,  $1.72 \times 10^3$ , and  $3.62 \times 10^3$ . In Group 2 (low-dose LPS group; 0.3 µg/ml), the average IgG<sub>4</sub>/IgE ratio was  $2.20 \times 10^3$ ,  $1.27 \times 10^3$ , and  $0.22 \times 10^3$ , respectively. In Group 3 (medium-dose LPS group; 1 µg/ml), the average IgG<sub>4</sub>/IgE ratio was  $1.19 \times 10^3$ ,  $0.69 \times 10^3$ , and  $0.56 \times 10^3$ , respectively. In Group 4 (high-dose LPS group; 3 µg/ml), the average IgG<sub>4</sub>/IgE ratio was  $1.59 \times 10^3$ ,  $1.64 \times 10^3$ , and  $0.65 \times 10^3$ , respectively. All groups exhibited significant differences of IgG<sub>4</sub>/IgE ratios, except at day-0. The highest IgG<sub>4</sub>/IgE ratio at day-4 and day-11 could be found in Group 1. The lowest IgG<sub>4</sub>/IgE ratio at day-4 could be found in Group 3, whilst the lowest ratio at day-11 could be found in Group 2 (Table 4).

**Table 2. Comparisons of total serum IgE (pg/mL) between the four groups (mean ± SEM).**

Group	n	IgE day 0	IgE day 4	IgE day 11
Group 1 (control)	4	5.69 ± 0.28	5.31 ± 0.76	5.06 ± 1.86
Group 2 (LPS Pg 0.3 µg/ml)	4	5.36 ± 0.19	9.26 ± 0.32	180.34 ± 10.42
Group 3 (LPS Pg 1 µg/ml)	4	10.27 ± 0.70	17.00 ± 1.69	112.90 ± 3.87
Group 4 (LPS Pg 3 µg/ml)	4	6.69 ± 0.61	14.79 ± 0.86	102.01 ± 11.04
F statistic	/	20.733	26.171	83.758
p value	/	0.071	0.006	0.047

\*Measured by one-way ANOVA (df1 = 3, df2 = 12, f table 3.490; significant at  $p < 0.05$ ).



**Figure 2. Longitudinal observation of serum IgG<sub>4</sub> levels following exposure to LPS Pg.**

**Subgroup analysis**

*Group 2 (0.3 µg/ml LPS Pg)*

Level of IgE were increased dramatically from day-0 to day-11 after experiments ( $5.36 \pm 0.19$  pg/ml to  $180.34 \pm 10.42$  pg/ml;  $p = 0.011$ ). Level of IgG<sub>4</sub> also increases significantly from day-0 to day-11 after experiments ( $11.76 \pm 0.85$  ng/ml to  $39.85 \pm 2.14$  ng/ml;  $p = 0.006$ ). On the other hand, IgG<sub>4</sub>/IgE ratio were decreased following experiments ( $2.20 \pm 0.13 \times 10^3$  to  $0.22 \pm 0.01 \times 10^3$ ;  $p = 0.014$ ) (Table 5).


*Group 3 (1 µg/ml LPS Pg)*

Level of IgE were raised dramatically from day-0 to day-11 after experiments ( $10.27 \pm 0.70$  pg/ml to  $112.90 \pm 3.87$  pg/ml;  $p = 0.003$ ). Level of IgG<sub>4</sub> also increased significantly from day-0 to day-11 after experiments ( $11.91 \pm 1.66$  ng/ml to  $63.6 \pm 10.76$  ng/ml;  $p = 0.027$ ). On the other hand, IgG<sub>4</sub>/IgE ratio declined following experiments ( $1.19 \pm 0.20 \times 10^3$  to  $0.56 \pm 0.09 \times 10^3$ ;  $p = 0.362$ ) (Table 6).

**Table 3. Comparisons of total serum IgG<sub>4</sub> (ng/mL) between the four groups (mean ± SEM).**

Group	n	IgG <sub>4</sub> day 0	IgG <sub>4</sub> day 4	IgG <sub>4</sub> day 11
Group 1 (control)	4	10.74 ± 1.41	8.34 ± 0.58	13.91 ± 0.99
Group 2 (LPS Pg 0.3 µg/ml)	4	11.76 ± 0.85	11.80 ± 0.83	39.85 ± 2.14
Group 3 (LPS Pg 1 µg/ml)	4	11.91 ± 1.66	11.98 ± 1.65	63.6 ± 10.76
Group 4 (LPS Pg 3 µg/ml)	4	10.14 ± 1.44	23.86 ± 1.59	63.74 ± 4.74
F statistic	/	0.379	29.265	15.665
p value	/	0.770	0.008	0.005

\*Measured by one-way ANOVA (df1 = 3, df2 = 12, f table 3.490; significant at p < 0.05).



**Figure 3. Comparisons of IgG<sub>4</sub>/IgE ratio between four groups (mean ± SEM).**

**Table 4. Comparisons of IgG<sub>4</sub>/IgE ratio (x10<sup>3</sup>) between the four groups (mean ± SEM)**

Group	n	IgG <sub>4</sub> /IgE day 0	IgG <sub>4</sub> /IgE day 4	IgG <sub>4</sub> /IgE day 11
Group 1 (control)	4	1.87 ± 0.18	1.72 ± 0.36	3.62 ± 0.85
Group 2 (LPS Pg 0.3 µg/ml)	4	2.20 ± 0.13	1.27 ± 0.08	0.22 ± 0.01
Group 3 (LPS Pg 1 µg/ml)	4	1.19 ± 0.20	0.69 ± 0.03	0.56 ± 0.09
Group 4 (LPS Pg 3 µg/ml)	4	1.59 ± 0.34	1.64 ± 0.20	0.65 ± 0.08
F statistic	/	3.418	5.032	13.600
p value	/	0.053	0.017	<0.001

\*Measured by one-way ANOVA (df1 = 3, df2 = 12, f table 3.490; significant at p < 0.05).

**Table 5. Comparisons of total serum IgE, IgG<sub>4</sub>, and IgG<sub>4</sub>/IgE ratio before and after treatment in Group 2 (exposure of 0.3 µg/mL LPS Pg) (mean ± SEM; n = 4).**

Time-point	IgE (pg/mL)	IgG <sub>4</sub> (ng/mL)	IgG <sub>4</sub> /IgE (x10 <sup>3</sup> )
Day-0 before treatment	5.36 ± 0.19	11.76 ± 0.85	2.20 ± 0.13
Day-4 after treatment	9.26 ± 0.32	11.80 ± 0.83	1.27 ± 0.08
Day-11 after treatment	180.34 ± 10.42	39.85 ± 2.14	0.22 ± 0.01
F statistic	93.924	178.233	71.969
p value	0.011	0.006	0.014

\*Measured by repeated measure ANOVA.

\*\*df times = 2, df error = 14, f table 3.739; significant at  $p < 0.05$ .

**Table 6. Comparisons of total serum IgE, IgG<sub>4</sub>, and IgG<sub>4</sub>/IgE ratio before and after treatment in Group 3 (exposure of 1 µg/mL LPS Pg) (mean ± SEM; n = 4).**

Time-point	IgE (pg/mL)	IgG <sub>4</sub> (ng/mL)	IgG <sub>4</sub> /IgE (x10 <sup>3</sup> )
Day-0 before treatment	10.27 ± 0.70	11.91 ± 1.66	1.19 ± 0.20
Day-4 after treatment	17.00 ± 1.69	11.98 ± 1.65	0.69 ± 0.03
Day-11 after treatment	112.90 ± 3.87	63.6 ± 10.76	0.56 ± 0.09
F statistic	294.526	35.437	1.760
p value	0.003	0.027	0.362

\*Measured by repeated measure ANOVA.

\*\*df times = 2, df error = 14, f table 3.739; significant at  $p < 0.05$ .

**Table 7. Comparisons of total serum IgE, IgG<sub>4</sub>, and IgG<sub>4</sub>/IgE ratio before and after treatment in Group 4 (exposure of 3 µg/mL LPS Pg) (mean ± SEM; n = 4).**

Time-point	IgE (pg/mL)	IgG <sub>4</sub> (ng/mL)	IgG <sub>4</sub> /IgE (x10 <sup>3</sup> )
Day-0 before treatment	6.69 ± 0.61	10.14 ± 1.44	1.59 ± 0.34
Day-4 after treatment	14.79 ± 0.86	23.86 ± 1.59	1.64 ± 0.20
Day-11 after treatment	102.01 ± 11.04	63.74 ± 4.74	0.65 ± 0.08
F statistic	111.386	32.929	7.841
p value	0.009	0.029	0.113

\*Measured by repeated measure ANOVA.

\*\*df times = 2, df error = 14, f table 3.739; significant at  $p < 0.05$ .

#### Group 4 (3 µg/ml LPS Pg)

Level of IgE were raised dramatically from day-0 to day-11 after experiments ( $6.69 \pm 0.61$  pg/ml to  $102.01 \pm 11.04$  pg/ml;  $p = 0.009$ ). Level of IgG<sub>4</sub> were also increase significantly from day-0 to day-11 after experiments ( $10.14 \pm 1.44$  ng/ml to  $63.74 \pm 4.74$  ng/ml;  $p = 0.029$ ). On the other hand, IgG<sub>4</sub>/IgE ratio declined following experiments ( $1.59 \pm 0.34 \times 10^3$  to  $0.65 \pm 0.08 \times 10^3$ ;  $p = 0.113$ ) (Table 7).

## Discussion

Several mechanisms have been suggested to alter atopic inflammatory responses following LPS Pg infection. One of the mechanisms proven in this study is an elevation of IgE antibody and reduction of IgG<sub>4</sub>/IgE ratio.<sup>24</sup> As far as we have known, Th-1 and Th-2 cells are not two different CD4+ T-cell subsets, but it represents polarized forms of the highly heterogenous CD4+ Th cell-mediated immune response. Host genetic and microenvironmental factors could have contributed with series of modulatory factors including:<sup>1</sup> the ligation of T-cell receptor (TCR);<sup>2</sup> the activation of costimulatory molecules and its particular components;<sup>3</sup> the predominance of an inflammatory cytokine in the local environment; and<sup>4</sup> the number of postactivation cell divisions following exposure to antigens. Down-regulation of the Th-1 cell is associated with depression



of cell-mediated immune response and stimulation of humoral immune response, thus pathogens are able to evade immune clearance.<sup>25</sup>

*Porphyromonas gingivalis* possess very sophisticated defense mechanisms against host immune responses. These pathogens produce capsules containing long chain LPS which is designed effectively to counter membrane attack complex. These long chain LPS can also downgrade cell-mediated immunity by shifting Th-1 into Th-2 which less dangerous to pathogens.<sup>26</sup> LPS may have an essential role in switching cell-mediated to humoral-mediated immune responses.<sup>27</sup> LPS Pg antigen is processed and presented on its surface with MHC-II molecule. Recent studies suggest an activation of alternative complement pathway, disruption of classical complement pathway, modulation of antigen presenting cells, and downregulation of anti-inflammatory cytokines are responsible for the Th2-skewed immune response following exposure to LPS Pg. Predominance shifting from Th-1 into Th-2 occurs in several extra-lymphoid tissues; the ideal site for *Porphyromonas gingivalis* is the oral cavity.<sup>28</sup>

Interleukin-4 (IL-4), which is produced by naive T cells, acts as autocrine manner known to be responsible for the differentiation and activation of Th-2 phenotype.<sup>29</sup> Guo et al (2014) shows upon the occurrence and development of allergic diseases, there is a complex pathobiology which results in an imbalance of Th-1/Th-2.<sup>30</sup> In an atopic disease such as bronchial asthma or urticaria, naive T cell can differentiate into Th-2 under IL-4-induced STAT6 and GATA-3 transcription factors.<sup>30</sup> Th-2 predominant immune response will automatically stimulate plasma cell to release IgE and IgG<sub>4</sub>.<sup>31</sup> Upon re-exposure of antigen or allergen, binding of the allergen to IgE orchestrates the adaptive immune system to initiate rapid sensitization. Frequent sensitization is a major risk factor for the development of allergic diseases such as urticaria, bronchial asthma, hay fever or atopic dermatitis/eczema.<sup>32</sup>

Our previous study used whole-cell body of *Porphyromonas gingivalis* to study different molecular responses in Wistar rats. Our first project studied the association between periodontal pathogen and host innate immunity. Exposure to *Porphyromonas gingivalis* had been shown to stimulate level of TLR2 and depress level of TLR4.<sup>33</sup> Our findings might indicate that several bacterial properties can turn-off host innate immunity and host inflammatory response. Our second project studied the association between periodontal pathogen and host adaptive immunity. We summarized that high dose CFU of Pg stimulates fold increase of Th-2 cytokines (IL-4, IL-5 and IL-13) and decrease of Th-1 cytokines (IFN- $\gamma$  and IL-17).<sup>34</sup> These were the cornerstone to continue our project in studying LPS as the most important component of these bacteria.

At this moment, both total IgE or specific IgE antibodies have little diagnostic value in the occurrence of allergic manifestation. Even total or specific IgE is increasing, yet the manifestation of allergy doesn't usually develop, since IgG<sub>4</sub> level also increases as a counter-regulator.<sup>35</sup> It means that even human or rat become susceptible to atopic allergy due to the increasing level of IgE, body mechanism is able to provide protection, with increased IgG<sub>4</sub> as a counter response to prevent manifestation of allergic diseases and immediate hypersensitivity. Thus, exposure of LPS Pg will develop chance of atopic and hypersensitivity markers, but manifestation of allergic reaction is a complex pattern.<sup>36</sup> IgG<sub>4</sub>/IgE ratio has closer accuracy to detect any alteration of atopic inflammatory pathway. Increase level of IgE, which isn't accompanied by IgG<sub>4</sub>, can be seen in patients with urticaria or atopic dermatitis.<sup>37</sup> IgE-switched B cells are much more likely to differentiate into plasma cells, whereas IgG<sub>4</sub>-switched B cells are less likely to differentiate.<sup>38</sup> This reason would explain why IgE antibody is the most dominant antibody in the development of atopic inflammatory pathway, whereas IgG<sub>4</sub> antibodies become prominent later during chronic non-atopic stimulation.<sup>39</sup> According to this reason, IgG<sub>4</sub>/IgE ratio may predict atopic responses more accurately than total or specific IgE level.

### Limitations and strengths

Several limitations should be highlighted. First, this study had limitations with regard to very small number of samples which can increase the likelihood of error and imprecision. Second, results from animal models often do not translate into replications in humans.<sup>40</sup> IgE antibody responses in Wistar rats are typically transient, whereas the atopic IgE response in human persists for many years.<sup>41</sup> Other crucial difference is IgG<sub>4</sub>/IgE ratio, which is usually much higher in the Wistar rats than humans.<sup>42-43</sup> These factors may have an impact on the interpretation of our results. Thus, the findings should be interpreted within the context of this study and its limitations. The strengths of the study were its high statistical power and the homogeneity of each group to enable comparison between groups and periods.

### Conclusion

Several experiments in rats indicate that exposure to LPS Pg may have a tendency to increase levels of IgE and IgG<sub>4</sub>. On the contrary, declining IgG<sub>4</sub>/IgE ratio following exposure to LPS Pg suggests the potential role of LPS Pg for isotype switching from IgG<sub>4</sub> to IgE. The results of the present study favor indirect isotype switching route for most IgE as secondary responses from LPS Pg infection that leads to systemic atopic inflammatory pathway.

## Data availability

### Underlying data

Figshare: Raw Data - Atopic Biomarker Changes after Exposure to *Porphyromonas gingivalis* Lipopolysaccharide: A Small Experimental Study in Wistar Rat, <https://doi.org/10.6084/m9.figshare.14350271.v1>.<sup>44</sup>

This project contains the following underlying data:

- Data fixed LPS grup A.sav (Group 1 results)
- Data fixed LPS grup B1.sav (Group 2 results)
- Data fixed LPS grup B2.sav (Group 3 results)
- Data fixed LPS grup B3.sav (Group 4 results)

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/) (CC-BY 4.0).

## Acknowledgments

This project is fully supported by Agung Sosiawan as Dean of Universitas Airlangga College of Dentistry and Coen Pramono as Director of Airlangga Oral and Dental Hospital. We would like to acknowledge Harjanto from Physiology Department and Indrawati Retno from Biochemistry Department for providing material and reagent generation. We also thank all lecturers and research assistants from Universitas Airlangga, who are willing to help in the technical aspect.

A previous version of this article is available on bioRxiv: <https://doi.org/10.1101/2021.01.14.426656>.

## References

1. Herrero ER, Fernandes S, Verspecht T, *et al.*: **Dysbiotic Biofilms Deregulate the Periodontal Inflammatory Response.** *J Dent Res.* 2018; **97**(5): 547–55.  
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Mazurek-Mochol M, Majorczyk E, Banach J, *et al.*: **The influence of KIR gene presence/absence polymorphisms on the development of periodontal disease in smokers and non-smokers.** *Cent Eur J Immunol.* 2017; **42**(4): 347–53.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Sperr M, Kundi M, Tursic V, *et al.*: **Prevalence of Comorbidities in Periodontitis Patients Compared to the General Austrian Population.** *J Periodontol.* 2018; **89**(1): 19–27.  
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Tarannum F, Faizuddin M: **Effect of gene polymorphisms on periodontal diseases.** *Indian. J Hum Genet.* 2012; **18**(1): 9–19.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Pathan MM, Bhat KG, Joshi VM: **Comparative evaluation of the efficacy of a herbal mouthwash and chlorhexidine mouthwash on select periodontal pathogens: An in vitro and ex vivo study.** *J Indian Soc Periodontol.* 2017; **21**(4): 270–275.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Rafiei M, Kiani F, Sayehmiri F, *et al.*: **Study of *Porphyromonas gingivalis* in periodontal diseases: A systematic review and meta-analysis.** *Med J Islam Repub Iran.* 2017; **31**: 62.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Dowarah R, Verma AK, Agarwal N, *et al.*: **Selection and characterization of probiotic lactic acid bacteria and its impact on growth, nutrient digestibility, health and antioxidant status in weaned piglets.** *PLoS One.* 2018; **13**(3): e0192978.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Fishbein AB, Fuleihan RL: **The hygiene hypothesis revisited: does exposure to infectious agents protect us from allergy?** *Curr Opin Pediatr.* 2012; **24**(1): 98–102.  
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Tse K, Horner AA: **Allergen tolerance versus the allergic march: the hygiene hypothesis revisited.** *Curr Allergy Asthma Rep.* 2008; **8**(6): 475–83.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Wang P, Duan D, Zhou X, *et al.*: **Relationship between expression of human gingival beta-defensins and levels of periodontopathogens in subgingival plaque.** *J Periodontol Res.* 2014; **50**(1): 113–122.  
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Tomitaa S, Komiya-Ito A, Imamura K, *et al.*: **Prevalence of *Aggregatibacter actinomycetemcomitans*, *Porphyromonas gingivalis* and *Tannerella forsythia* in Japanese patients with generalized chronic and aggressive periodontitis.** *Microb Pathog.* 2013; **61-62**: 11–15.  
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Ting Z, Hong X, Zhaohui Y: **Relationships of five periodontal pathogens causing subgingival plaque in patients with chronic periodontitis under different periodontal conditions.** *West China J Stomatol.* 2013; **5**: 518–21.  
[PubMed Abstract](#)
13. Amano A, Kuboniwa A, Nakagawa I, *et al.*: **Prevalence of specific genotypes of *Porphyromonas gingivalis* fimA and periodontal health status.** *J Dent Res.* 2000; **79**(9): 1664–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Lu R, Feng L, Gao X, *et al.*: **Relationship between volatile fatty acids and *Porphyromonas gingivalis* and *Treponema denticola* in gingival crevicular fluids of patients with aggressive periodontitis.** *Beijing Da Xue Xue Bao.* 2013; **45**(1): 12–16.  
[PubMed Abstract](#)
15. Scapoli L, Girardi A, Palmieri A, *et al.*: **Microflora and periodontal disease.** *Dent Res J (Isfahan).* 2012; **9**(2): S202–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Carinci F, Scapoli L, Girardi A, *et al.*: **Oral microflora and periodontal disease: new technology for diagnosis in dentistry.** *Ann Stomatol.* 2013; **5**(2): 170–3.  
[PubMed Abstract](#) | [Free Full Text](#)
17. Avila-Campos MJ, Velasquez-Melendez G: **Prevalence of putative periodontopathogens from periodontal patients and healthy subjects in São Paulo SP Brazil.** *Rev Inst Med trop S. Paulo.* 2002; **44**(1): 1–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)

18. Wilson M, Lopatin D, Osborne G, *et al.*: **Prevalence of *Treponema denticola* and *Porphyromonas gingivalis* in plaque from periodontally-healthy and periodontally-diseased sites.** *J Med Microbiol.* 1993; **38**: 406–10.  
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Riep B, Edesi-Neuss L, Claessen F, *et al.*: **Are putative periodontal pathogens reliable diagnostic markers?** *J Clin Microbiol.* 2009; **47**(6): 1705–11.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Kato A, Imai K, Ochiai K, *et al.*: **Higher Prevalence of Epstein-Barr Virus DNA in Deeper Periodontal Pockets of Chronic Periodontitis in Japanese Patients.** *PLoS ONE.* 2013; **8**(8): e71990.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Kato A, Imai K, Ochiai K, *et al.*: **Salivary detection of periodontopathic bacteria in Fanconi's anemia patients.** *Anaerobe.* 2013; **24**: 32–35.  
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Rafiei M, Kiani F, Sayehmiri F, *et al.*: **Study of *Porphyromonas gingivalis* in periodontal diseases: A systematic review and meta-analysis.** *Med J Islam Repub Iran.* 2017; **31**: 62.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Okamoto S, Taniuchi S, Sudo K, *et al.*: **Predictive value of IgE/IgG<sub>4</sub> antibody ratio in children with egg allergy.** *Allergy Asthma Clin Immunol.* 2012; **8**: 9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Portnoy J: **IgE in Clinical Allergy and Allergy Diagnosis.** [accessed on 1 July 2018].  
[Reference Source](#)
25. Herman RA, Ladics GS: **Allergenic sensitization versus elicitation risk criteria for novel food proteins - short communication.** *Regul Toxicol Pharmacol.* 2018; **94**: 283–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Matthews CR, Joshi V, de Jager M, *et al.*: **Host-bacterial interactions during induction and resolution of experimental gingivitis in current smokers.** *J Periodontol.* 2013; **84**(1): 32–40.  
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Finlay BB, McFadden G: **Anti-Immunology: Evasion of the Host Immune System by Bacterial and Viral Pathogens.** *Cell.* 2006; **124**(4): 767–782.  
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Schmid-Hempel P: **Immune defence, parasite evasion strategies and their relevance for 'macroscopic phenomena' such as virulence.** *Philos Trans R Soc Lond B Biol Sci.* 2009; **364**(1513): 85–98.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Theodorou GL, Marousi S, Ellul J, *et al.*: **T helper 1 (Th1)/Th2 cytokine expression shift of peripheral blood CD4+ and CD8+ T cells in patients at the post-acute phase of stroke.** *Clin Exp Immunol.* 2008; **152**(3): 456–63.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Guo HW, Yun CX, Hou GH, *et al.*: **Mangiferin attenuates TH1/TH2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model.** *PLoS One.* 2014; **9**: e100394.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Ettinger R, Karnell JL, Henault J, *et al.*: **Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses.** *Autoimmunity.* 2017; **50**(1): 25–36.  
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Varricchi G, Raap U, Rivellese F, *et al.*: **Human mast cells and basophils-How are they similar how are they different?** *Immunol Rev.* 2018; **282**(1): 8–34.  
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Nelwan SC, Nugraha RA, Endaryanto A, *et al.*: **Modulating toll-like receptor-mediated inflammatory responses following exposure of whole cell and lipopolysaccharide component from *Porphyromonas gingivalis* in wistar rat models.** *Eur J Dent.* 2017; **11**(4): 422–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Nelwan SC, Nugraha RA, Endaryanto A, *et al.*: **Converging findings from linkage between periodontal pathogen with atopic and allergic immune response.** *Cytokine.* 2019; **113**: 89–98.  
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Saulite I, Hoetzenecker W, Guenova E, *et al.*: **Skin Test Reactivity to Hymenoptera Venom after Venom Immunotherapy Correlates Inversely with the IgG/IgE Ratio.** *Int Arch Allergy Immunol.* 2017; **174**(3–4): 190–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Garman L, Smith K, Muns EE, *et al.*: **Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed Vaccination.** *Clin Vaccine Immunol.* 2016; **23**(8): 664–71.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Deo SS, Mistry KJ, Kakade AM, *et al.*: **Role played by Th2 type cytokines in IgE mediated allergy and asthma.** *Lung India.* 2010; **27**(2): 66–71.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Kubo M: **T follicular helper and TH2 cells in allergic responses.** *Allergol Int.* 2017; **66**(3): 377–81.  
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Zhang Y, Fear DJ, Willis-Owen SA, *et al.*: **Global gene regulation during activation of immunoglobulin class switching in human B cells.** *Sci Rep.* 2016; **6**: 37988.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Platts-Mills TA, Vaughan JW, Blumenthal K, *et al.*: **Serum IgG and IgG<sub>4</sub> antibodies to Fel d 1 among children exposed to 20 microg Fel d 1 at home: relevance of a nonallergic modified Th2 response.** *Int Arch Allergy Immunol.* 2001; **124**: 126–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Ramadani F, Bowen H, Upton N, *et al.*: **Ontogeny of human IgE-expressing B cells and plasma cells.** *Allergy.* 2017; **72**(1): 66–76.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Aalberse RC, Platts-Mills TA, Rispens T: **The Developmental History of IgE and IgG<sub>4</sub> Antibodies in Relation to Atopy, Eosinophilic Esophagitis, and the Modified TH2 Response.** *Curr Allergy Asthma Rep.* 2016; **16**(6): 45.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Hatipoğlu U, Subramanian A, Campbell T, *et al.*: **Intrasubject Variability in Total IgE Levels in Patients with Moderate to Severe Persistent Allergic Asthma Over 1 Year.** *J Allergy Clin Immunol Pract.* 2016; **4**(4): 691–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Nelwan SC, Nugraha RA, Endaryanto A, *et al.*: **Raw Data - Atopic Biomarker Changes after Exposure to *Porphyromonas gingivalis* Lipopolysaccharide: A Small Experimental Study in Wistar Rat.** *figshare. Dataset.* 2021.  
[Publisher Full Text](#)

## Abbreviations

ANOVA	analysis of variant
BCR	B cell receptor
CD-40	Cluster Differentiation-40
CFU	colony-forming unit
CSR	class-switch recombination
df	degree of freedom
ELISA	enzyme-linked immunosorbent assay
FDA	Food and Drug Administration
HDM	house dust mite
IACUC	Institutional Animal Care and Use Committee
IFN- $\gamma$	gamma-Interferon
IgE	immunoglobulin-E
IgG <sub>4</sub>	immunoglobulin-G <sub>4</sub>

IL	interleukin
LLPC	long-lived plasma cell
LPS	lipopolysaccharide
mAb	monoclonal antibody
MAC	membrane attack complex
MHC	major histocompatibility complex
NIH	National Institutes of Health
NGS	next-generation sequencing
NK	natural killer cells
OIT	oral immunotherapy
PAMP	pathogen-associated molecular patterns
PCR	Polymerase Chain Reaction
Pg	<i>Porphyromonas gingivalis</i>
SD	standard deviation
SEM	standard error of the mean
SPSS	Statistical Package for the Social Sciences
Th-1	type-1 helper T-cells
Th-2	type-2 helper T-cells
TNF- $\alpha$	Tumor Necrosis Factor- $\alpha$

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**